Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
about
Outcomes from unrelated donor hematopoietic stem cell transplantationChildren's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Treatment of adolescent and young adults with acute lymphoblastic leukemiaBlood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemiaDeclining childhood and adolescent cancer mortalityMarkedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).Improved prognosis for older adolescents with acute lymphoblastic leukemia.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Challenging issues in pediatric oncologyProtracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remissionImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.Unique MRI findings as an early predictor of osteonecrosis in pediatric acute lymphoblastic leukemia.Principles and Recommendations for the Provision of Healthcare in Canada to Adolescent and Young Adult-Aged Cancer Patients and SurvivorsThe adolescent and young adult with cancer: state of the art-- acute leukemias.Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia.The successful integration of research and care: how pediatric oncology became the subspecialty in which research defines the standard of care.Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Treatment of acute lymphoblastic leukemia in adolescents and young adults.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia.Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?The treatment of adolescents and young adults with acute lymphoblastic leukemia.Therapeutic approaches to haematological malignancies in adolescents and young adults.Emerging drugs for acute lymphocytic leukemia.Acute lymphoblastic leukemia in adolescents and young adults.Pediatric haematopoiesis and related malignancies.Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries.Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases.Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-FrankAsparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.
P2860
Q27027854-DF4D3BDF-0E90-4420-A521-495FF5928F2DQ33711119-DC5493EA-43F2-4EAA-AB9A-F80BC07C7C74Q33920153-0C989329-551F-41FB-A0A3-3498389FDF2DQ34009088-91728AA4-6BAF-4419-AE45-7C57341D46D2Q34060045-500DD319-7208-4E1B-8CED-70B666E10AA4Q34454611-A27895E8-1369-4A63-B5D6-D51D5765802EQ34550540-CA1A37D0-9495-4F65-9A72-70C3CC14B77EQ34679298-69704F59-E8FA-4C2A-AB7E-D52406DDF219Q34764504-D0AEAB91-0A43-4229-A927-4C7FF0245965Q35602419-B282DFBA-8D93-4AD4-A7D8-CFBD951E4940Q35758669-4A20B2C8-AF4F-43E5-B170-A6B1B320E3ACQ36023505-33E0DF1E-30D9-46DB-A5B8-9F45299AF953Q36058255-31A379C1-3A81-491D-A0BF-50E85F3E1808Q36422310-262C70D3-009A-4DCE-A1DE-DE5F88A9D007Q36753192-14A539A3-4242-4373-B0D3-CFEBF053F507Q37134753-63CC2DE3-5494-4D68-BC87-4550D5B429F1Q37549450-757ACC13-9ACB-4924-8D88-39DD7DEF294CQ37833967-861D7CB9-8F93-4461-AB50-9F6D4E4A7786Q37883008-66D700F9-3023-4939-B21B-3351AF819842Q37899785-F5701B48-29B1-4E34-BC28-E7FBE3E5131DQ37914185-DDEC9FD4-2BC5-43EF-A0CA-C9E9B32B7E6EQ37919867-07432118-ED9D-477D-811D-59799BB94052Q37990381-0E3B1CF1-1F9D-4E51-A3CA-6F7D8D7F1FD8Q38079288-AB0894D1-0732-421C-8845-B0542732A92AQ38087853-5CE9AB02-FAB1-411C-AFC8-F5027107CB02Q38096307-2A7483A2-19B8-4803-8144-B1957016B8C1Q38134399-98F7452B-F404-4898-818D-211DCCD0E7EEQ38172586-004F817D-4F3F-495F-AD5C-5A5A4E8DCD93Q39192991-F35BEEA6-3927-412C-9C9F-C12F5CDA1A1EQ39425967-CDE8F8D0-36F8-479B-9B90-C01E711254FAQ39510856-6F3358E3-63C9-42C4-954A-35A7FD2FC2E9Q39657505-85216FE4-0B52-4F57-BDD1-056D106E383CQ39992854-1ED5D419-8EBD-46D5-8C73-9A5BC2CCC7F7Q40044204-32F15E29-A654-4175-855B-5EC475ED2DA1Q40097280-25C19711-6F7F-424B-85A4-01EEBD983429Q40243523-D533A5C5-93D4-4610-BC65-C550B51FA449Q40427765-8599B37F-8494-4334-BA2B-411035FD2E7EQ40754724-2226DFE1-E7EB-441B-83F2-9F7DBBF0EEE3Q40781300-7AC51360-23BF-483E-9F73-9D8FA7057B04Q44232638-E0365140-0006-423B-A998-01615A1F50DD
P2860
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Young adults with acute lympho ...... the children's oncology group.
@ast
Young adults with acute lympho ...... the children's oncology group.
@en
Young adults with acute lympho ...... the children's oncology group.
@nl
type
label
Young adults with acute lympho ...... the children's oncology group.
@ast
Young adults with acute lympho ...... the children's oncology group.
@en
Young adults with acute lympho ...... the children's oncology group.
@nl
prefLabel
Young adults with acute lympho ...... the children's oncology group.
@ast
Young adults with acute lympho ...... the children's oncology group.
@en
Young adults with acute lympho ...... the children's oncology group.
@nl
P2093
P2860
P50
P356
P1476
Young adults with acute lympho ...... the children's oncology group.
@en
P2093
Caroline Hastings
David R Freyer
Harland Sather
James B Nachman
Leonard A Mattano
Meenakshi Devidas
Peter G Steinherz
P2860
P304
P356
10.1200/JCO.2008.20.8959
P407
P577
2009-10-05T00:00:00Z